Evidence map›Paper›PMID 31805696›Full record

ArticleJournal of clinical medicine2019

Metabolic Syndrome Including Glycated Hemoglobin A1c in Adults: Is It Time to Change?

Iván Cavero-Redondo, Vicente Martínez-Vizcaíno, Celia Álvarez-Bueno, Cristina Agudo-Conde, Cristina Lugones-Sánchez, Luis García-Ortiz

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Metabolic syndrome and immune-related adverse events.Cancer immunology, immunotherapy : CII · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Metabolic Syndrome in Fasting and Non-Fasting Participants: The UAE Healthy Future Study.International journal of environmental research and public health · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Iván Cavero-RedondoUniversidad de Castilla-La Mancha, Health and Social Research Center, 16071 Cuenca, Spain.ORCID 0000-0003-2617-0430
Vicente Martínez-VizcaínoUniversidad de Castilla-La Mancha, Health and Social Research Center, 16071 Cuenca, Spain.ORCID 0000-0001-6121-7893
Celia Álvarez-BuenoUniversidad de Castilla-La Mancha, Health and Social Research Center, 16071 Cuenca, Spain.ORCID 0000-0002-6176-1618
Cristina Agudo-CondeInstitute of Biomedical Research of Salamanca (IBSAL), Primary Care Research Unit of Salamanca (APISAL), Health Service of Castilla y León (SACyL), 37003 Salamanca, Spain.
Cristina Lugones-SánchezInstitute of Biomedical Research of Salamanca (IBSAL), Primary Care Research Unit of Salamanca (APISAL), Health Service of Castilla y León (SACyL), 37003 Salamanca, Spain.
Luis García-OrtizInstitute of Biomedical Research of Salamanca (IBSAL), Primary Care Research Unit of Salamanca (APISAL), Health Service of Castilla y León (SACyL), 37003 Salamanca, Spain.

Funding

Autonomous Government of Castilla and León GRS 770/B/13Carlos III Health Institute FIS: PI12/01474Carlos III Health Institute FIS:PI13/00058Carlos III Health Institute FIS:PI13/00618Carlos III Health Institute FIS:PI13/01526Carlos III Health Institute FIS: PI13/01635Carlos III Health Institute FIS:PI13/02528Carlos III Health Institute RETICS: RD12/0005
6 · The paper itself

Abstract

(1) Background: To assess the suitability of replacing conventional markers used for insulin resistance and dysglycemia by HbA1c in both the quantitative and qualitative metabolic syndrome (MetS) definition criteria; (2) Methods: Confirmatory factorial analysis was used to compare three quantitative definitions of MetS that consisted of many single-factor models, one of which included HbA1c as the dysglycemia indicator. After that, the model with the better goodness-of-fit was selected. Furthermore, a new MetS qualitative definition was proposed by replacing fasting plasma glucose with HbA1c > 5.7% in the International Diabetes Federation (IDF) definition. The clinical performance of these two MetS criteria (IDF and IDF-modified including HbA1c as the dysglycemia indicator) to predict vascular damage (pulse wave velocity [PWv], intima media thickness [IMT] and albumin-to-creatinine ratio [ACR]) was estimated; (3) Results: The single-factor model including HbA1c showed the better goodness-of-fit (χ

Indexed as

HbA1cmetabolic syndromevascular health

Identifiers

PMID31805696
PMCPMC6947260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.